US Patent

US11590136 — Topical formulation for a JAK inhibitor

Method of Use · Assigned to Incyte Corp · Expires 2031-05-20 · 5y remaining

Vulnerability score 59/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a topical formulation for applying a JAK inhibitor to the skin for treating skin disorders.

USPTO Abstract

This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3229`	—	ruxolitinib-phosphate

Patent Metadata

Patent number: US11590136
Jurisdiction: US
Classification: Method of Use
Expires: 2031-05-20
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.